<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282904</url>
  </required_header>
  <id_info>
    <org_study_id>150007</org_study_id>
    <secondary_id>15-I-0007</secondary_id>
    <nct_id>NCT02282904</nct_id>
  </id_info>
  <brief_title>Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide</brief_title>
  <official_title>Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Post-Transplant Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Chronic Granulomatous Disease (CGD) causes immune system problems. Treatment is usually a
      bone marrow transplant from a fully matched donor. Researchers want to try using partially
      matched donors for patients who do not have a fully matched donor available. The researchers
      will also use the drug cyclophosphamide to try to improve the outcomes when using a partially
      matched donor.

      Objective:

      - To learn the effectiveness of using cyclophosphamide with a transplant from a partially
      matched donor in treating CGD.

      Eligibility:

      - Recipients: age 2-65 with CGD with an ongoing infection that has not been cured by standard
      treatment and no fully matched donor available in an appropriate timeframe.

      Design:

        -  Recipients will:

             -  be admitted to the hospital 2 weeks before transplant.

             -  be screened with blood and urine tests, breathing and heart health tests, X-rays,
                and/or magnetic resonance imaging. They may have a bone marrow aspiration and
                biopsy.

        -  meet with a social worker and dentist.

        -  get chemotherapy, radiation, and other medicines.

        -  get an intravenous (IV) catheter in their chest.

        -  have the transplant.

        -  get more medicines and standard supportive care.

        -  have blood drawn frequently.

        -  have to stay in the Washington, D.C. area for 3 months post-transplant.

        -  be followed closely for the first 6 months, and then less frequently for at least 5
           years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic transplant using HLA matched donors, both related and unrelated, has proven
      curative for patients with various immunodeficiencies, including those with ongoing
      infections. However donor availability remains a limiting factor in the application of this
      treatment modality. The use of haploidentical donors has in the past been fraught with a
      greater rate of complications related to both higher rates of GvHD and delayed
      immunorecovery. Newer transplant regimens appear to have diminished these risks and improved
      outcomes. We propose using a subablative conditioning regimen followed by post-transplant
      cyclophosphamide for patients with CGD who do not have an HLA matched donor but whose
      circumstances necessitate the use of a potentially curative, albeit high-risk treatment
      modality.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 23, 2014</start_date>
  <completion_date type="Actual">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">April 10, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Efficacy of This Allogeneic Transplant Approach in Reconstituting Normal Hematopoiesis and Reversing the Clinical Phenotype of CGD</measure>
    <time_frame>5 years</time_frame>
    <description>Patient will have donor chimerism of greater than 20% and resolution of infection or autoimmunity at end of follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Safety of This Allogeneic HSCT Approach in Patients With CGD Including Transplant Related Toxicity, the Incidence of Acute and Chronic Graft-versus-host Disease, Immune Reconstitution, Overalland Disease-free Survival.</measure>
    <time_frame>1 year post transplant</time_frame>
    <description>1. Stable chimerism as indicated by 30-50% myeloid engraftment and 50% lymphoid engraftment as assessed by 1 year post transplant. 2. Immune reconstitution levels with DHR as a marker of normal neutrophil function by 1 year post transplant. 3. GvHD grades of less than 3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Chronic Granulomatous Disease</condition>
  <arm_group>
    <arm_group_label>CGD Recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).</description>
    <arm_group_label>CGD Recipient</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor peripheral blood stem cells.</intervention_name>
    <description>Infuse donor graft.</description>
    <arm_group_label>CGD Recipient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide post transplant</intervention_name>
    <description>50 mg/kg/d IV infused over 90 minutes. Day +3 and +4</description>
    <arm_group_label>CGD Recipient</arm_group_label>
    <other_name>Cytoxan post transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body 200cGy</intervention_name>
    <description>Day -1</description>
    <arm_group_label>CGD Recipient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14.5 mg/kg IV over one hour Day -6 and -5</description>
    <arm_group_label>CGD Recipient</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2 over 30 minutes Day -6 through Day -2</description>
    <arm_group_label>CGD Recipient</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2</description>
    <arm_group_label>CGD Recipient</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Must have sufficient complications from underlying disease to warrant undergoing
             transplantation

          -  Ages 2 years - 65 years

          -  No appropriate HLA matched donor (available donor has greater than 1 mismatch or the
             single mismatch is not at DQ for unrelated donors (including cord blood products), or
             no available 6 out of 6 HLA matched related donor), or patients who may have an
             unrelated donor, but whose clinical status is such that the time required to obtain an
             unrelated donor would be life threatening.

          -  HLA haploidentical family donor graft available.

          -  Ability to comprehend and willingness to sign the informed consent or have a
             parent/guardian consent if the donor is a minor; assent being obtained from minors as
             appropriate

          -  Must be HIV negative

          -  Must not be pregnant (confirmed by a negative serum beta-human chorionic gonadotropin
             (Beta-hCG) for women of child-bearing potential) or breastfeeding

          -  Must be able to stay within one hour s travel of the NIH for the first 3 months after
             transplantation and have a family member or other designated companion to stay with
             during the post-transplant period.

          -  Must provide a durable power of attorney for health care decisions to an appropriate
             adult relative or guardian in accordance to NIH Form-200 NIH Durable Power of Attorney
             for Health Care Decision Making.

          -  Where appropriate, subjects must agree to use contraception for 3 months
             post-transplant

        EXCLUSION CRITERIA:

          -  Major anticipated illness or organ failure incompatible with survival from
             Allo-transplant

          -  Inadequate collection from prospective donors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth M Kang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005.</citation>
    <PMID>18489989</PMID>
  </reference>
  <reference>
    <citation>Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood. 2011 Dec 1;118(23):6006-17. doi: 10.1182/blood-2011-07-338822. Epub 2011 Sep 14. Review.</citation>
    <PMID>21921045</PMID>
  </reference>
  <reference>
    <citation>Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, Fuchs EJ. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep. 2011 Jun 22;3 Suppl 2:e15. doi: 10.4081/pr.2011.s2.e15.</citation>
    <PMID>22053277</PMID>
  </reference>
  <verification_date>December 10, 2019</verification_date>
  <study_first_submitted>November 4, 2014</study_first_submitted>
  <study_first_submitted_qc>November 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <results_first_submitted>April 13, 2020</results_first_submitted>
  <results_first_submitted_qc>April 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Granulomatous Disease</keyword>
  <keyword>Halo-Identical Protocol</keyword>
  <keyword>Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02282904/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02282904/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CGD Recipient</title>
          <description>CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
Sirolimus: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Donor peripheral blood stem cells.: Infuse donor graft.
Cyclophosphamide post transplant: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Total body 200cGy: Day -1
Cyclophosphamide: 14.5 mg/kg IV over one hour Day -6 and -5
Fludarabine: 30 mg/m2 over 30 minutes Day -6 through Day -2
Busulfan: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7">Patient accrual was stopped early, and the protocol closed after completing followup</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CGD Recipient</title>
          <description>CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
Sirolimus: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Donor peripheral blood stem cells.: Infuse donor graft.
Cyclophosphamide post transplant: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Total body 200cGy: Day -1
Cyclophosphamide: 14.5 mg/kg IV over one hour Day -6 and -5
Fludarabine: 30 mg/m2 over 30 minutes Day -6 through Day -2
Busulfan: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.42" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection present</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Autoimmunity present</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Determine the Efficacy of This Allogeneic Transplant Approach in Reconstituting Normal Hematopoiesis and Reversing the Clinical Phenotype of CGD</title>
        <description>Patient will have donor chimerism of greater than 20% and resolution of infection or autoimmunity at end of follow up</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGD Recipient</title>
            <description>CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
Sirolimus: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Donor peripheral blood stem cells.: Infuse donor graft.
Cyclophosphamide post transplant: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Total body 200cGy: Day -1
Cyclophosphamide: 14.5 mg/kg IV over one hour Day -6 and -5
Fludarabine: 30 mg/m2 over 30 minutes Day -6 through Day -2
Busulfan: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Efficacy of This Allogeneic Transplant Approach in Reconstituting Normal Hematopoiesis and Reversing the Clinical Phenotype of CGD</title>
          <description>Patient will have donor chimerism of greater than 20% and resolution of infection or autoimmunity at end of follow up</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greater than 20% donor chimerism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resolution of inflammation or infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Safety of This Allogeneic HSCT Approach in Patients With CGD Including Transplant Related Toxicity, the Incidence of Acute and Chronic Graft-versus-host Disease, Immune Reconstitution, Overalland Disease-free Survival.</title>
        <description>1. Stable chimerism as indicated by 30-50% myeloid engraftment and 50% lymphoid engraftment as assessed by 1 year post transplant. 2. Immune reconstitution levels with DHR as a marker of normal neutrophil function by 1 year post transplant. 3. GvHD grades of less than 3.</description>
        <time_frame>1 year post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGD Recipient</title>
            <description>CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
Sirolimus: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Donor peripheral blood stem cells.: Infuse donor graft.
Cyclophosphamide post transplant: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Total body 200cGy: Day -1
Cyclophosphamide: 14.5 mg/kg IV over one hour Day -6 and -5
Fludarabine: 30 mg/m2 over 30 minutes Day -6 through Day -2
Busulfan: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2</description>
          </group>
        </group_list>
        <measure>
          <title>To Determine the Safety of This Allogeneic HSCT Approach in Patients With CGD Including Transplant Related Toxicity, the Incidence of Acute and Chronic Graft-versus-host Disease, Immune Reconstitution, Overalland Disease-free Survival.</title>
          <description>1. Stable chimerism as indicated by 30-50% myeloid engraftment and 50% lymphoid engraftment as assessed by 1 year post transplant. 2. Immune reconstitution levels with DHR as a marker of normal neutrophil function by 1 year post transplant. 3. GvHD grades of less than 3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with stable chimerism at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with normal DHR at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Acute (Grade 3 or higher) GvHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with Chronic GvHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disease Free Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected over 5 years (2015 to 2019)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CGD Recipient</title>
          <description>CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
Sirolimus: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).
Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Donor peripheral blood stem cells.: Infuse donor graft.
Cyclophosphamide post transplant: 50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
Total body 200cGy: Day -1
Cyclophosphamide: 14.5 mg/kg IV over one hour Day -6 and -5
Fludarabine: 30 mg/m2 over 30 minutes Day -6 through Day -2
Busulfan: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Post transplant lymphoproliferative disease</sub_title>
                <description>Development of a clonal outgrowth of cells due to suppression of the immune system</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Acute GvHD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <description>Development of irritation and bleeding from the bladder due to infection and/or chemotherapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild GvHD</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth Kang</name_or_title>
      <organization>NIAID</organization>
      <phone>3014027567</phone>
      <email>ekang@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

